HSPs as targets of the transplant immunome are translocated to the myeloma cell surface translocation after bortezomib treatment. Amo-1 myeloma cells were treated with 10 nM bortezomib for 24 hours followed by flow cytometric staining with HSP60-, HSP71-, and HSP90-directed antibodies (B). Untreated cells served as control (A). Isotype antibody or secondary antibody only served as staining control.